UY33973A - Métodos de tratamiento dirigido de degeneración lobular frontotemporal. - Google Patents
Métodos de tratamiento dirigido de degeneración lobular frontotemporal.Info
- Publication number
- UY33973A UY33973A UY0001033973A UY33973A UY33973A UY 33973 A UY33973 A UY 33973A UY 0001033973 A UY0001033973 A UY 0001033973A UY 33973 A UY33973 A UY 33973A UY 33973 A UY33973 A UY 33973A
- Authority
- UY
- Uruguay
- Prior art keywords
- frontotemporary
- methods
- directed treatment
- lobular degeneration
- lobular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Tratamiento dirigido a sujetos que sufren de degeneración lobular frontotemporal, mediante el uso de agentes dirigidos a la DLFT, como se describe en la presente invención. En particular, los agentes dirigidos a la DLFT proporcionados en esta solicitud demuestran alta penetración en el cerebro, hecho que disminuye las cuestiones de riesgo asociadas con la administración periférica. Asimismo, los agentes dirigidos a la DLFT de la presente invención, cuando son administrados a un sujeto seleccionado para el tratamiento sobre la base de los resultados de un ensayo de diagnóstico de DLFT, ofrecen el tratamiento dirigido de la DLFT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467989P | 2011-03-26 | 2011-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33973A true UY33973A (es) | 2012-10-31 |
Family
ID=45931040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001033973A UY33973A (es) | 2011-03-26 | 2012-03-26 | Métodos de tratamiento dirigido de degeneración lobular frontotemporal. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140179678A1 (es) |
| EP (1) | EP2691099A1 (es) |
| JP (2) | JP5995956B2 (es) |
| CN (2) | CN105748484A (es) |
| AR (1) | AR085572A1 (es) |
| AU (1) | AU2012236852A1 (es) |
| CA (1) | CA2831291A1 (es) |
| IL (1) | IL228405A0 (es) |
| MX (1) | MX2013011096A (es) |
| RU (1) | RU2013147810A (es) |
| TW (1) | TW201247205A (es) |
| UY (1) | UY33973A (es) |
| WO (1) | WO2012135097A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143300A1 (en) * | 2014-03-21 | 2015-09-24 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| US20220251084A1 (en) * | 2019-06-12 | 2022-08-11 | Arkuda Therapeutics | Progranulin modulators and methods of using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| CN105481788A (zh) * | 2006-10-28 | 2016-04-13 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US20090291444A1 (en) * | 2008-03-31 | 2009-11-26 | Jason Eriksen | Methods and materials for detecting and treating dementia |
| WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| WO2009137462A2 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
-
2012
- 2012-03-26 TW TW101110441A patent/TW201247205A/zh unknown
- 2012-03-26 UY UY0001033973A patent/UY33973A/es not_active Application Discontinuation
- 2012-03-26 AU AU2012236852A patent/AU2012236852A1/en not_active Abandoned
- 2012-03-26 MX MX2013011096A patent/MX2013011096A/es not_active Application Discontinuation
- 2012-03-26 AR ARP120101007A patent/AR085572A1/es unknown
- 2012-03-26 US US14/007,572 patent/US20140179678A1/en not_active Abandoned
- 2012-03-26 JP JP2014502654A patent/JP5995956B2/ja not_active Expired - Fee Related
- 2012-03-26 WO PCT/US2012/030527 patent/WO2012135097A1/en active Application Filing
- 2012-03-26 RU RU2013147810/15A patent/RU2013147810A/ru not_active Application Discontinuation
- 2012-03-26 CN CN201610143729.3A patent/CN105748484A/zh active Pending
- 2012-03-26 CN CN201280025073.5A patent/CN103561747B/zh not_active Expired - Fee Related
- 2012-03-26 CA CA2831291A patent/CA2831291A1/en not_active Abandoned
- 2012-03-26 EP EP12712497.2A patent/EP2691099A1/en not_active Withdrawn
-
2013
- 2013-09-12 IL IL228405A patent/IL228405A0/en unknown
-
2016
- 2016-08-23 JP JP2016162758A patent/JP2017019826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105748484A (zh) | 2016-07-13 |
| EP2691099A1 (en) | 2014-02-05 |
| MX2013011096A (es) | 2014-06-06 |
| CN103561747A (zh) | 2014-02-05 |
| AR085572A1 (es) | 2013-10-09 |
| JP2017019826A (ja) | 2017-01-26 |
| US20140179678A1 (en) | 2014-06-26 |
| JP5995956B2 (ja) | 2016-09-21 |
| WO2012135097A1 (en) | 2012-10-04 |
| CA2831291A1 (en) | 2012-10-04 |
| TW201247205A (en) | 2012-12-01 |
| IL228405A0 (en) | 2013-12-31 |
| NZ615177A (en) | 2016-02-26 |
| RU2013147810A (ru) | 2015-05-10 |
| AU2012236852A1 (en) | 2013-09-26 |
| JP2014511848A (ja) | 2014-05-19 |
| CN103561747B (zh) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| UA110813C2 (uk) | Лікування ліподистрофії | |
| BR112013032229A2 (pt) | método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição | |
| LT2726511T (lt) | Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| JO3131B1 (ar) | مركبات كيميائية | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CR20130539A (es) | Triazolopiridinas | |
| UY33936A (es) | Derivados de fluoro-piridinona útiles como agentesantibacterianos. | |
| UY34654A (es) | Inhibidores de la beta-secretasa | |
| MX2014007840A (es) | Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp). | |
| BR112013024211A2 (pt) | tratamento de tumores sólidos | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| EP2712291A4 (en) | N1 AND N2 CARBAMOYL-1,2,3-TRIAZOL SERINE HYDROLASE INHIBITORS AND METHOD THEREFOR | |
| UY34141A (es) | Composiciones de limpieza de sal líquida | |
| UY34158A (es) | Composicion herbicida | |
| UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
| EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
| MY178390A (en) | Inhibitors of iap | |
| UY33976A (es) | Derivados de pirazolo-pirimidina. | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| UA111333C2 (uk) | Спосіб одержання l-аргінінової солі периндроприлу | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| EP2739764A4 (en) | ION SOURCE | |
| IN2014DN00254A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20201019 |